Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. Rapid correction of low vitamin D status in nursing home residents 3. 2008 Exclusive Survey—Earnings: Good news for primary care income 4. Medicare pay-for-reporting effort draws fire from frustrated doctors 5. Allopurinol-induced recurrent dress syndrome: Pathophysiology and treatment
Top Ten Searches
rheumatoid arthritis lupus polymyalgia sjogrens fibromyalgia amyloidosis vasculitis urate raynauds myositisYour Article Summary
Pathogenesis of bone disorders in HIV infection
International Journal of Clinical Rheumatology, 05/13/09
Venhoff N et al. - Risk factors are multifactorial and include a low body mass index, smoking and possibly viral replication itself and antiretroviral treatment. Treatment with tenofovir in particular may induce osteomalacia in some patients. HIV infection is also complicated by osteonecrosis, which is approximately 100-fold more prevalent than in the general population. Biphosphonates represent the first-line therapy for osteoporosis in HIV-infected patients, but their effects on fractures have not yet been evaluated.
Today in Bone Metabolism...keeping you current
Receive free subspecialty "5-minute updates" via email
Osteonecrosis of the jaw correlated to bisphosphonate therapy in non-oncologic patients: Clinicopathological features of 24 patients
Journal of Rheumatology, 11/09/09
Bisphosphonate therapy: When not to monitor BMD
The Journal of Family Practice, 11/02/09
Effect of alendronate on bone metabolic indices and bone mineral density in patients treated with high-dose glucocorticoid: A prospective study
Osteoporosis International, 11/25/09
Today in Clinical Pharmacology...keeping you current
Receive free subspecialty "5-minute updates" via email
Osteonecrosis of the jaw correlated to bisphosphonate therapy in non-oncologic patients: Clinicopathological features of 24 patients
Journal of Rheumatology, 11/09/09
Treatment of polymyalgia rheumatica
Archives of Internal Medicine, 11/10/09
Cancer risk in patients with rheumatoid arthritis treated with anti-tumor necrosis factor [alpha] therapies: Does the risk change with the time since start of treatment?
Arthritis & Rheumatism, 11/05/09
Sponsor
Article Search
Sponsor


See Latest Articles


